A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
IMVT-1401-2501: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD)
Sponsor: Immunovant Sciences GmbH
Listed as NCT05907668, this PHASE2 trial focuses on Graves Disease and remains completed. Sponsored by Immunovant Sciences GmbH, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE2
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immunovant Sciences GmbH
For direct contact, visit the study record on ClinicalTrials.gov .